Equities Analysts Issue Forecasts for NRIX Q1 Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Nurix Therapeutics in a research report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings of ($0.89) per share for the quarter. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.99) per share. Leerink Partnrs also issued estimates for Nurix Therapeutics’ Q2 2025 earnings at ($0.93) EPS.

NRIX has been the subject of a number of other research reports. Leerink Partners started coverage on shares of Nurix Therapeutics in a research report on Monday. They issued a “market perform” rating and a $16.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. BMO Capital Markets began coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target on the stock. HC Wainwright upped their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley lifted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.88.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $13.90 on Wednesday. Nurix Therapeutics has a 52-week low of $11.90 and a 52-week high of $29.56. The stock has a market cap of $1.05 billion, a P/E ratio of -4.81 and a beta of 2.18. The firm has a 50 day moving average price of $17.22 and a 200 day moving average price of $20.93.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%.

Institutional Investors Weigh In On Nurix Therapeutics

A number of large investors have recently added to or reduced their stakes in NRIX. Amalgamated Bank increased its holdings in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Nurix Therapeutics by 2.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,025 shares of the company’s stock valued at $585,000 after buying an additional 642 shares during the last quarter. Corebridge Financial Inc. raised its holdings in Nurix Therapeutics by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 34,907 shares of the company’s stock valued at $658,000 after acquiring an additional 770 shares during the period. Kennedy Capital Management LLC lifted its position in Nurix Therapeutics by 0.7% during the fourth quarter. Kennedy Capital Management LLC now owns 114,623 shares of the company’s stock worth $2,159,000 after acquiring an additional 785 shares during the last quarter. Finally, US Bancorp DE boosted its holdings in shares of Nurix Therapeutics by 144.7% during the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after acquiring an additional 842 shares during the period.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. This represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the sale, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,326 shares of company stock valued at $213,449. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.